Management of Decreased Gastric Motility

Pathophysiologic Basis for Treatment

• Decreased gastric motility results from impaired antral contractions, pyloric dysfunction, and loss of coordinated gastric-duodenal motor activity, according to the American Gastroenterological Association 4

Dietary Management (First-Line Intervention)

• Implement 5-6 small meals daily focusing on low-fat, low-fiber foods to minimize gastric distension and promote faster emptying, as recommended by the American College of Gastroenterology 1, 2
• Replace solid foods with liquids in patients with severe symptoms who cannot tolerate solids, as suggested by the American Gastroenterological Association 4, 1

Pharmacologic Management Algorithm

• Start metoclopramide 10 mg three times daily, taken 30 minutes before meals, as the only FDA-approved medication for gastroparesis, according to the American College of Gastroenterology 1, 3
• Treat for at least 4 weeks to determine efficacy in diabetic gastroparesis patients, as recommended by the American Diabetes Association 1, 2

Antiemetic Therapy for Symptom Control

• Use 5-HT3 receptor antagonists for refractory nausea by blocking serotonin receptors in the chemoreceptor trigger zone, as suggested by the American Society of Clinical Oncology 2
• Phenothiazines reduce nausea and vomiting through central antidopaminergic mechanisms in the area postrema, according to the American Gastroenterological Association 4, 1, 2

Pain Management in Gastroparesis

• Tricyclic antidepressants act as neuromodulators for patients with significant visceral abdominal pain, as recommended by the American College of Gastroenterology 2

Nutritional Support for Refractory Cases

• Try enteral nutrition via jejunostomy tube feeding as first step before home parenteral nutrition in patients unable to meet energy needs with oral nutrition alone, as suggested by the American Society for Parenteral and Enteral Nutrition 5

Management of Chronic Intestinal Pseudo-Obstruction (CIPO)

• Always attempt a trial with prokinetics even though these agents help only a minority of patients with generalized motility disorders, according to the American Gastroenterological Association 5, 3

Critical Pitfalls to Avoid

• Withdraw opioids in gastroparesis patients as they directly impair gastrointestinal motility, as recommended by the American College of Gastroenterology 3
• Discontinue or avoid GLP-1 agonists, which can worsen gastroparesis symptoms, according to the American Diabetes Association 1, 2

Monitoring and Reassessment

• Evaluate treatment effectiveness at 4 weeks for metoclopramide and adjust therapy accordingly, as suggested by the American College of Gastroenterology 1, 2
• Monitor for extrapyramidal symptoms with metoclopramide use and reassess at 12 weeks before continuing beyond this timeframe, according to the American Psychiatric Association 2